These results suggest that MA acts as a reversal agent that can enhance resistant NSCLC cells sensitive to the EGFR inhibitor, GE, through FTO/M6A/MYC axis-mediated downregulation of BCRP and MRP7. The gene discussed is ABCG2; the disease is non-small cell lung carcinoma.